Weight-loss injections have fallen under the spotlight in Hong Kong after the Post discovered over-the-counter sellers operating locally, and a recent study found that nearly one in two residents was overweight or obese.
The Post’s investigation found the prescription-only medicines were available for purchase on some online platforms and at a pharmacy without the need for a doctor’s approval, sparking concerns about potential health risks.
The Post looks into the matter and examines the loopholes and associated risks.
1. Which brands are approved in Hong Kong?
Major brands of injections approved for use in Hong Kong to treat obesity include Wegovy, Ozempic and Saxenda, all produced by Danish drug maker Novo Nordisk, and United States drug giant Eli Lilly’s Mounjaro.
These drugs are administered as injections using pre-filled pens that can be self-injected into the upper arm, thigh or stomach.
They mainly work as appetite suppressants by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which makes people feel fuller.
2. What’s the appeal?
Obesity has become an increasing concern among Hongkongers, as the condition can increase the risk of multiple diseases, such as type 2 diabetes, cardiovascular diseases and cancer.
